BioSpace News Archive

The United States Centers for Disease Control and Prevention, the United States Food and Drug Administration, and the United States Food Safety and Inspection Service are investigating an outbreak of Escherichia coli O157, commonly called E. coli, that is linked to romaine lettuce coming from the Salinas, California growing region in the United States. E. coli can cause a serious, life-threatening illness.

The International Water, Sanitation and Hygiene Foundation’s (IWSH) Community Plumbing Challenge (CPC) program has completed its latest installment, a Design Week project in the coastal village of Kampung Nelayan Untia.

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) at the Society for Neuro-Oncology (SNO) Annual Meeting.

We are providing an important update into our investigation of an outbreak of E. coli O157:H7 illnesses which have sickened more than 40 people in 16 states.

ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced that new preclinical data characterising ASLAN003 as a potential treatment for acute myeloid leukaemia has been published in the November issue of HaematologicaJournal.

Dr. Reddy’s Laboratories Ltd. announced the launch of Doxercalciferol Injection, 4 mcg/2 mL Multiple-Dose Vials, the therapeutic generic equivalent of Hectorol® Injection 4 mcg/2 mL Multiple-Dose Vials, approved by the U.S. Food and Drug Administration..

Industry expert judges and attendees picked the four winners of the Oregon Bioscience Association’s 2019 Research Fast Pitch and Company Pitch Fest competition

Sunovion Pharmaceuticals Inc. (Sunovion) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD) in response to the January 29, 2019 Complete Response Letter (CRL).

Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related to merger and acquisition agreements.